Blog Coverage Cesca Therapeutics Announces Encouraging Results from a Study of its Treatment of Chronic Non-healing Ulcers

Upcoming AWS Coverage on Medtronic Post-Earnings Results

LONDON, UK / ACCESSWIRE / March 16, 2017 / Active Wall St. blog coverage looks at the headline from Cesca Therapeutics Inc. (NASDAQ: KOOL) as the Company reported on March 15, 2017, encouraging data from a study evaluating the use of autologous platelet rich plasma (PRP) for the treatment of chronic non-healing ulcers. Results from the 24 patient study entitled “Treatment of chronic non-healing ulcers using autologous platelet rich plasma: a case series” were published in the peer-reviewed, Journal of Biomedical Science. The study was led by researchers from TotipotentRX, a subsidiary of Cesca Therapeutics, and Fortis Memorial Research Institute. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of Cesca Therapeutics’ competitors within the Medical Appliances & Equipment space, Medtronic PLC (NYSE: MDT), reported on February 21, 2017, its financial results for Q3 FY17, which ended January 27, 2017. AWS will be initiating a research report on Medtronic in the coming days.

Today, AWS is promoting its blog coverage on KOOL; touching on MDT. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

The Study

Cesca Therapeutics stated that the study was conducted with 24 patients with one wound/ulcer of varying etiology were treated with a single dose of PRP injections around the wound alongside a topical administration of autologous platelet gel. The process was completed at the patient’s bedside in a single session within 30 minutes. The Company noted that healing of the wound/ulcer was observed in patients as early as 4 weeks after the PRP treatment with a mean healing time of 8.2 weeks ±1.9. All patients demonstrated healing of the wound/ulcer, with 17 (70.8%) patients showing a 90% reduction in wound size and 3 (12.5%) patients showing an 80-90% reduction over the course of the 24 week follow-up. The study also reported that there were no adverse events on the day of treatment or during the patient’s 24 week follow-up, demonstrating a good safety profile for the treatment of chronic non-healing wounds/ulcers.

Dr. Venkatesh Ponemone, Study Director and Executive Director of TotipotentRX commented:

“We are very pleased with the data from the study and believe that the use of PRP is a major breakthrough for the treatment of chronic non-healing wounds and ulcers. Using Cesca’s point-of-care platform, we are able to develop rapid cell based therapies at the patient’s bedside within 30 minutes significantly reducing the risk and costs associated with current standard of care treatments.”

Chronic non-healing ulcers pose a significant health risk worldwide affecting an estimated 2 million-6 million people in the United States alone, and are a major cause of non-traumatic lower limb amputations. Despite a variety of standard of care treatments, many chronic ulcers fail to heal or persist for months/years and/or recur after healing, requiring additional advanced wound care therapies. Platelet Rich Plasma, however, has been a major breakthrough in the arena of vascular therapies allowing the use of a patient’s own body cells for wound/ulcer treatment, providing the necessary growth factors that enhance tissue healing.

$5 Million Line of Credit

On March 13, 2017, Cesca Therapeutics announced that it has closed a revolving line of credit (“RLOC”) with Boyalife Investment Fund II, Inc. The non-collaterized RLOC is for a term of five years and is generally drawable at Cesca’s discretion. Additionally, Cesca also announced that it has set-up a wholly-owned subsidiary, ThermoGenesis Corp., to separately own and operate, and thereby strengthen its device business. The clinical development activities will remain with Cesca, the parent Company.

“This RLOC with Boyalife gives us the financial resources to offer our expanding product pipeline to new and existing customers in the US and international markets without having to dilute the Company’s stockholders at current market price,” said Chris Xu, Cesca’s interim Chief Executive Officer, “Automation in cellular processing and a point-of-care therapy is the core business for ThermoGenesis. Setting up the device division in in its own entity is intended to enable Cesca to more effectively manage the device business’s performance and growth strategy. Our goal is to make ThermoGenesis cash-flow neutral within next 12 months.”

Stock Performance

At the close of trading session on Wednesday, March 15, 2017, following the announcement, Cesca Therapeutics’ stock price rose 8.36% to end the day at $3.11. A total volume of 3.07 million shares were exchanged during the session, which was above the 3-month average volume of 182.57 thousand shares. At Wednesday’s closing price, the stock’s net capitalization stands at $30.79 million.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 457433